GAAP

Titan Reports 16% Increase in Production While Lowering Costs

Retrieved on: 
Friday, March 22, 2024
Titan, Element, QA/QC, ISO/IEC, Mining, Silver, ICP-AES, ALS, ICP, Zinc, Copper, Aqua regia, Lead, Empire, News, Table, AES, Master of Science, Bank statement, ESM, SME, Crescent, GAAP, Analysis, Mud Pond, RDI, Digestion, Audit

Deepening of the lower Mahler ramp system provided access to high-grade ore in the Lower Mahler mining zone that supported strong grades and record metal production.

Key Points: 
  • Deepening of the lower Mahler ramp system provided access to high-grade ore in the Lower Mahler mining zone that supported strong grades and record metal production.
  • It is expected that ore from this zone will continue to support budgeted zinc grades for FY2024.
  • Major projects completed include the counter-weight rail replacement for the service cage and purchase of a telehandler for underground material movement.
  • A total of 7,984 ft was drilled, with mineralization intercepted 600 ft down dip from the current active faces of Lower Mahler.

Sow Good Reports Strong Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Friday, March 22, 2024
Cracker Barrel, Target, Gateway Group, Partnership, Candy, Acquisition, Table, Stock, Net operating loss, Adjustment, SKU, GAAP, OTCQB, Video game

IRVING, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- Sow Good Inc. (OTCQB: SOWG) (“Sow Good” or “the Company”), a trailblazer in the freeze dried candy and treat industry, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • “Our strong 2023 results reflect our swift momentum and progress as a first mover in the freeze dried candy space,” said Claudia Goldfarb, CEO of Sow Good.
  • Same Year-Ago Quarter
    Revenue in the fourth quarter of 2023 increased significantly to $9.5 million compared to $47.1 thousand in the fourth quarter of 2022.
  • Operating expenses in the fourth quarter of 2023 were $1.6 million compared to $6.4 million in the fourth quarter of 2022.
  • Sow Good will conduct a conference call today at 10:00 A.M. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2023.

Abacus Life Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Growth, Webcast, Intangibles, Policy, ROE, ABL, Asset, GAAP, Income tax, Eastern Time Zone, Total, Video game

ORLANDO, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading buyer of life insurance policies and vertically integrated alternative asset manager specializing in specialty insurance products, today reported results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Total revenue for the fourth quarter of 2023 grew 25% to $23.6 million, compared to $18.8 million in the prior-year period.
  • Adjusted net income for the fourth quarter of 2023 was $5.9 million, compared to $11.0 million in the prior-year period.
  • Adjusted EBITDA for the fourth quarter of 2023 was $11.0 million, compared to $11.1 million in the prior-year period.
  • Total operating expenses for the fourth quarter of 2023 were $20.0 million, compared to $4.4 million in the prior-year period.

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, U.S. FDA, Conference, Growth, Journey, Agreement, FY, IGA, Microbiota, Risk, New Drug Application, Patient, Food and Drug Administration, Rosacea, Hyperhidrosis, NDA, Red, News, Adjustment, Dermatology, Clinical trial, Erythema, Doxycycline, Safety, GAAP, Food, Marketing, FDA, CEA, Total, PDUFA, Pharmaceutical industry

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points: 
  • ET to discuss the financial results and provide a business update
    SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
  • Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
  • In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
  • In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Flex, Growth, Urology, Communication, Patient, Telephone, Sale, TRUST, General surgery, Software, Security (finance), Motion, Freezing, LUNA, Surgeon, Bank statement, Gynaecology, Investment, Annual report, Triangle Park (Quezon City), GAAP, File, Optimism, FDA, CIS, Health, Nursing

“As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.

Key Points: 
  • “As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.
  • During the fourth quarter of 2023, the Company initiated five new Senhance Surgical System placements, one in Germany, one in Romania, two in the CIS region and one in Japan at Nagoya University Hospital.
  • In 2023, surgeons performed over 3,550 procedures utilizing the Senhance System, representing a 13% increase over the previous year.
  • In addition to regulatory milestones, the Company has introduced four Senhance System programs dedicated to pediatric departments in the U.S. and internationally.

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
GAAP, Research, Net, Investment, Instil, Video game

DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.

Key Points: 
  • DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.
  • Research and development expenses were $2.0 million and $39.6 million for the fourth quarter and full year ended December 31, 2023, respectively, compared to $20.7 million and $141.1 million for the fourth quarter and full year ended December 31, 2022, respectively.
  • Restructuring and impairment charges were $0.2 million and $72.0 million for the fourth quarter and full year ended December 31, 2023, respectively, compared to $23.2 million for the fourth quarter and full year ended December 31, 2022.
  • Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

ATTENTION NASDAQ: INVZ INVESTORS: Contact Berger Montague About an Innoviz Technologies Class Action Lawsuit

Retrieved on: 
Thursday, March 21, 2024
Original equipment manufacturer, FY, Volkswagen, Perception, Lead, Aptiv, News, BMW, GAAP, Court

PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ) on behalf of purchasers of Innoviz’s securities between April 21, 2021 and February 28, 2023, inclusive (the “Class Period”).

Key Points: 
  • PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ) on behalf of purchasers of Innoviz’s securities between April 21, 2021 and February 28, 2023, inclusive (the “Class Period”).
  • Investor Deadline: Investors who purchased or acquired Innoviz securities during the Class Period may, no later than May 14, 2024, seek to be appointed as a lead plaintiff representative of the class.
  • Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970.
  • Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Intuitive Machines Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Machine, Houston Airport System, Growth, FY, Artemis, International, White, City, History, IPO, Free cash flow, United, Adjustment, Moon, NASA, Intuitive Machines, Depreciation, GAAP, CLPS, Air Force Research Laboratory, Intuition, Economics

Participants may access the call at 1-877-451-6152, international callers may use 1-201-389-0879, and request to join the Intuitive Machines earnings call.

Key Points: 
  • Participants may access the call at 1-877-451-6152, international callers may use 1-201-389-0879, and request to join the Intuitive Machines earnings call.
  • A link to the live webcast of the earnings conference call will be made available on the investors portion of the Intuitive Machines’ website at https://investors.intuitivemachines.com.
  • A webcast replay will be available through the same link on the investors portion of the Intuitive Machines’ website at https://investors.intuitivemachines.com.
  • Other companies, including companies in Intuitive Machines’ industry, may calculate Adjusted EBITDA differently, which reduces its usefulness as a comparative measure.

Innovative Food Holdings, Inc. Reports Financial Results for Fourth Quarter and Fiscal Year 2023

Retrieved on: 
Thursday, March 21, 2024
E-commerce, Working capital, USDA, GAAP, Rationalization, OTCQB, Marketing, Advertising, Food industry, Pharmaceutical industry

BONITA SPRINGS, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Innovative Food Holdings, Inc. (OTCQB: IVFH) (“IVFH” or the “Company”), a national seller of gourmet specialty foods to professional chefs, today reported its financial results for the fourth quarter and fiscal year of 2023.

Key Points: 
  • Bill Bennett, Chief Executive Officer of IVFH, remarked, “2023 marked an incredible turnaround for Innovative Food Holdings.
  • Excluding the effect of restructuring, severance, and one-time related outflows and expenses during the year, the company has become cash flow positive.
  • Revenues in fiscal year 2023 decreased 8.5% to $72.2 million, impacted by a 6.5% decrease in specialty foodservice revenue.
  • The following table sets forth IVFH’s revenue by business category for the year ended December 31, 2023, and December 31, 2022 (unaudited):

CareCloud Reports Full Year 2023 Results

Retrieved on: 
Thursday, March 21, 2024
CareCloud, Depreciation, GAAP

SOMERSET, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company” or “CareCloud”) (Nasdaq: CCLD, CCLDP and CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced financial and operational results for the year ended December 31, 2023.

Key Points: 
  • SOMERSET, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company” or “CareCloud”) (Nasdaq: CCLD, CCLDP and CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced financial and operational results for the year ended December 31, 2023.
  • A. Hadi Chaudhry, CEO and President of CareCloud remarked “We are focused on cost alignment initiatives with the goal of restoring profitability.
  • Fourth quarter 2023 GAAP net loss was $43.7 million, compared to net income of $499,000 in the same period last year.
  • During the fourth quarter 2023 and for the full year 2023, cash flow from operations was approximately $3.7 million and $15.5 million, respectively.